34. A.A. Burns, J. Vider, H. Ow, E. Herz, O. Penate-Medina, M. Baumgart et al., Fluorescent
silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 9(1), 442–
448 (2009)
35. M. Benezra, O. Penate-Medina, P.B. Zanzonico, D. Schaer, H. Ow, A. Burns et al.,
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human
melanoma. J. Clin. Invest. 121(7), 2768–2780 (2011)
36. M. Benezra, E. Phillips, M. Overholtzer, P.B. Zanzonico, E. Tuominen, U. Wiesner et al.,
Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular
processes in a concentration-dependent manner. Small 11(14), 1721–1732 (2015)
37. H. Ow, D.R. Larson, M. Srivastava, B.A. Baird, W.W. Webb, U. Wiesner, Bright and stable
core-shell fluorescent silica nanoparticles. Nano Lett. 5(1), 113–117 (2005)
38. K. Ma, C. Mendoza, M. Hanson, U. Werner-Zwanziger, J. Zwanziger, U. Wiesner, Control of
ultrasmall sub-10 nm ligand-functionalized fluorescent core–shell silica nanoparticle growth
in water. Chem. Mater. 27(11), 4119–4133 (2015)
39. K. Ma, D.H. Zhang, Y. Cong, U. Wiesner, Elucidating the mechanism of silica nanoparticle
PEGylation processes using fluorescence correlation spectroscopies. Chem. Mater. 28(5),
1537–1545 (2016)
40. F. Chen, H. Hong, Y. Zhang, H.F. Valdovinos, S. Shi, G.S. Kwon et al., In vivo tumor
targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous
silica nanoparticles. ACS Nano. 7(10), 9027–9039 (2013)
41. F. Chen, H. Hong, S. Goel, S.A. Graves, H. Orbay, E.B. Ehlerding et al., In vivo tumor
vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano. 9(4), 3926–
3934 (2015)
42. F. Chen, H. Hong, S. Shi, S. Goel, H.F. Valdovinos, R. Hernandez et al., Engineering of
hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting
efficacy. Sci. Rep. 4, 5080 (2014)
43. F. Chen, T.R. Nayak, S. Goel, H.F. Valdovinos, H. Hong, C.P. Theuer et al., In vivo tumor
vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol. Pharm. 11(11), 4007–4014 (2014)
44. F. Chen, S. Goel, H.F. Valdovinos, H. Luo, R. Hernandez, T.E. Barnhart et al., In vivo
integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica
nanoparticles. ACS Nano. 9(8), 7950–7959 (2015)
45. S. Goel, F. Chen, S. Luan, H.F. Valdovinos, S. Shi, S.A. Graves et al., Engineering
intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for
in vivo biodistribution and tumor targeting studies. Adv. Sci. (Weinh.) 3(11), 1600122 (2016)
46. P.A. Ellison, F. Chen, S. Goel, T.E. Barnhart, R.J. Nickles, O.T. DeJesus et al., Intrinsic and
stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl.
Mater. Interfaces 9(8), 6772–6781 (2017)
47. F. Chen, H.F. Valdovinos, R. Hernandez, S. Goel, T.E. Barnhart, W. Cai, Intrinsic
radiolabeling of Titanium-45 using mesoporous silica nanoparticles. Acta Pharmacol. Sin.
38(6), 907–913 (2017)
48. S. Goel, F. Chen, H. Hong, H.F. Valdovinos, R. Hernandez, S. Shi et al., VEGF 121 -
conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl.
Mater. Interfaces 6(23), 21677–21685 (2014)
49. S. Shi, C. Xu, K. Yang, S. Goel, H.F. Valdovinos, H. Luo et al., Chelator-free radiolabeling of
nanographene: breaking the stereotype of chelation. Angew. Chem. Int. Ed. Engl. 56(11),
2889–2892 (2017)
50. S. Shi, K. Yang, H. Hong, F. Chen, H.F. Valdovinos, S. Goel et al., VEGFR targeting leads to
significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials 39, 39–46
(2015)
51. H. Hong, K. Yang, Y. Zhang, J.W. Engle, L. Feng, Y. Yang et al., In vivo targeting and
imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS
Nano. 6(3), 2361–2370 (2012)
326
F. Chen
silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 9(1), 442–
448 (2009)
35. M. Benezra, O. Penate-Medina, P.B. Zanzonico, D. Schaer, H. Ow, A. Burns et al.,
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human
melanoma. J. Clin. Invest. 121(7), 2768–2780 (2011)
36. M. Benezra, E. Phillips, M. Overholtzer, P.B. Zanzonico, E. Tuominen, U. Wiesner et al.,
Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular
processes in a concentration-dependent manner. Small 11(14), 1721–1732 (2015)
37. H. Ow, D.R. Larson, M. Srivastava, B.A. Baird, W.W. Webb, U. Wiesner, Bright and stable
core-shell fluorescent silica nanoparticles. Nano Lett. 5(1), 113–117 (2005)
38. K. Ma, C. Mendoza, M. Hanson, U. Werner-Zwanziger, J. Zwanziger, U. Wiesner, Control of
ultrasmall sub-10 nm ligand-functionalized fluorescent core–shell silica nanoparticle growth
in water. Chem. Mater. 27(11), 4119–4133 (2015)
39. K. Ma, D.H. Zhang, Y. Cong, U. Wiesner, Elucidating the mechanism of silica nanoparticle
PEGylation processes using fluorescence correlation spectroscopies. Chem. Mater. 28(5),
1537–1545 (2016)
40. F. Chen, H. Hong, Y. Zhang, H.F. Valdovinos, S. Shi, G.S. Kwon et al., In vivo tumor
targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous
silica nanoparticles. ACS Nano. 7(10), 9027–9039 (2013)
41. F. Chen, H. Hong, S. Goel, S.A. Graves, H. Orbay, E.B. Ehlerding et al., In vivo tumor
vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano. 9(4), 3926–
3934 (2015)
42. F. Chen, H. Hong, S. Shi, S. Goel, H.F. Valdovinos, R. Hernandez et al., Engineering of
hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting
efficacy. Sci. Rep. 4, 5080 (2014)
43. F. Chen, T.R. Nayak, S. Goel, H.F. Valdovinos, H. Hong, C.P. Theuer et al., In vivo tumor
vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol. Pharm. 11(11), 4007–4014 (2014)
44. F. Chen, S. Goel, H.F. Valdovinos, H. Luo, R. Hernandez, T.E. Barnhart et al., In vivo
integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica
nanoparticles. ACS Nano. 9(8), 7950–7959 (2015)
45. S. Goel, F. Chen, S. Luan, H.F. Valdovinos, S. Shi, S.A. Graves et al., Engineering
intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for
in vivo biodistribution and tumor targeting studies. Adv. Sci. (Weinh.) 3(11), 1600122 (2016)
46. P.A. Ellison, F. Chen, S. Goel, T.E. Barnhart, R.J. Nickles, O.T. DeJesus et al., Intrinsic and
stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl.
Mater. Interfaces 9(8), 6772–6781 (2017)
47. F. Chen, H.F. Valdovinos, R. Hernandez, S. Goel, T.E. Barnhart, W. Cai, Intrinsic
radiolabeling of Titanium-45 using mesoporous silica nanoparticles. Acta Pharmacol. Sin.
38(6), 907–913 (2017)
48. S. Goel, F. Chen, H. Hong, H.F. Valdovinos, R. Hernandez, S. Shi et al., VEGF 121 -
conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl.
Mater. Interfaces 6(23), 21677–21685 (2014)
49. S. Shi, C. Xu, K. Yang, S. Goel, H.F. Valdovinos, H. Luo et al., Chelator-free radiolabeling of
nanographene: breaking the stereotype of chelation. Angew. Chem. Int. Ed. Engl. 56(11),
2889–2892 (2017)
50. S. Shi, K. Yang, H. Hong, F. Chen, H.F. Valdovinos, S. Goel et al., VEGFR targeting leads to
significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials 39, 39–46
(2015)
51. H. Hong, K. Yang, Y. Zhang, J.W. Engle, L. Feng, Y. Yang et al., In vivo targeting and
imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS
Nano. 6(3), 2361–2370 (2012)
326
F. Chen